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1. Editorial introduction and purpose
The ongoing and seemingly endless COVID-19 (SARS-
CoV-2) pandemic is not only a global health crisis, but it
has also highlighted a number of pre-existing problems, in-
cluding access to health care, greater severity of COVID-
related complications for those with poor lifestyle behav-
iors of cardiometabolic diseases, and the added complexities
underserved populations face with seeking and gaining ac-
cess to essential healthcare services. Below we pose some
of the many questions of interest to chronic disease man-
agement (summarized in Fig. 1), with an emphasis on car-
diometabolic disease, during and following COVID-19. On
behalf of HL-PIVOT (Healthy Living for Pandemic Event
Protection) and Exercise is Medicine® (EIM) Underserved &
Community Health, this special issue aims to expand the dis-
course related to the short- and long-term impact of COVID-
19 on individual and public health. Below we pose some of
the many topics of interest to chronic disease management,
with an emphasis on cardiometabolic disease. during and
following COVID-19. The intention of this section is to ig-
nite interest in this special issue and spur continued discourse
from authors across the biomedical spectrum.
2. Topics of interest
2.1 Long-term cardiometabolic health complications
Although the clinical manifestations of COVID-19 are
dominated by respiratory symptoms, cardiometabolic phys-
iology has not escaped the wrath of this virus. There are re-
ports that cardiometabolic complications increase the likeli-
hood of contracting COVID-19 as well as symptom severity.
For example, a recent Cochrane review of 220 studies from
across the globe, reported that hypertension (46%), diabetes
(22%), and ischemic heart disease (11%) are highly prevalent
among those hospitalized for COVID-19 [1]. Additionally,
the review reported that there has been a substantial inci-
dence of a wide range of cardiovascular complications, in-
cluding arrhythmias (9.3%), heart failure (6.8%) and throm-
botic complications (7.4%). It should be acknowledged that
the Cochrane review focused on patients who were hospi-
talized. Whether or not cardiovascular complications oc-
cur in those infected with milder COVID-19 clearly warrants
further attention. Additional questions that need to be ad-
dressed with respect to COVID-19-related cardiometabolic
complications include: what is the underlying pathophysiol-
ogy? Which populations are at heightened risk? What are
the key risk factors? And what type of data is being collected
to help address such questions?
2.2 Lifestyle behaviors during and beyond COVID-19
Wholesale restrictions were imposed by governments
worldwide to slow the progression of the COVID-19 pan-
demic. Enforced lockdowns resulted in an immediate switch
to remote and flexible working for billions worldwide, lead-
ing to immediate changes in lifestyle behaviors. One of the
most highlighted issues is the effect of lockdowns on in-
creased sedentary time and reduced physical activity. While
recommendations for home-based exercise routines were
promoted by leading health organizations [2, 3], reductions
in population-level physical activity, health status and in-
creased sedentary behavior has been observed [4]. A perti-
nent question and area of concern are whether activities and
lifestyle behaviors enforced by the pandemic will return to
pre-pandemic ‘norms’ or will the influence be sustained as
part of a COVID-19 syndemic affecting population health
and wellbeing?
Fig. 1. Important considerations for managing chronic disease during and following the COVID-19 (SARS-CoV-2) pandemic include: (i) car-
diometabolic health complications (e.g., what are the long-term impacts to vascular health?); (ii) lifestyle behaviors (e.g., will COVID-19 affect long-term
lifestyle behavioral patterns?); (iii) the health gap (e.g., will COVID-19 widen the gap for underserved populations?); (iv) healthcare adaptations (e.g., what
adaptations should be made to clinical practices?); (v) economic (e.g., will COVID-19 affect direct and indirect healthcare costs?); and (vi) the need for data
(e.g., what data is being collected to help better understand the long-term cardiometabolic consequences of COVID-19 infection?).
2.3 Health gap
The broadening of health inequalities has been exposed by
COVID-19, especially in those fromunderserved populations
[5]. Existing inequalities, health epidemics and social de-
terminants of health have rendered those from underserved
populations at greater risk ofCOVID-19 infection, long-term
morbidity, and mortality [6]. Sustained periods of transmis-
sion and the subsequent impact of prolonged recovery will
undoubtedly pose long term risks to those from underserved
communities, who undoubtedly will require prolonged ac-
cess to health care services. Whilst efforts from international
governments are prioritizing restoring the socio-economic
factors affected by COVID-19, we believe efforts should also
prioritize and address the widening health inequalities that
could lead to an increase and widening of health inequalities.
2.4 Healthcare adaptations
The international response to COVID-19 has been drastic
and immediate to prevent sustained progression and trans-
mission of the virus. While international collaboration has
led to the development of efficacious vaccination programs
and gradual easing of international restrictions, the threat of
COVID-19 and the lasting impact upon health status is ever-
present. Healthcare providers and researchers are developing
resources and support programs for a novel virus to cater for
the broad challenges being experienced by patients follow-
ing a COVID-19 infection [7], but the lasting impact has yet
to be determined. Cardiovascular complications are part of a
complex symptomprofile thatwill require tailored support to
improve and restore functional status to pre-COVID-19 lev-
els [8]. The challenge and longitudinal impact will undoubt-
edly be a feature in clinical practice for the foreseeable future
and we invite colleagues to consider the specific approaches
in design and delivery of bespoke interventions. We also in-
vite discussion pertaining to the long-term adaptations that
will be needed in order to support the increasing and complex
patient profile.
2.5 National and global economies
Prior to the COVID-19 pandemic, cardiovascular disease
was the leading cause of death and the most costly in terms of
health care expenditure [9]. As discussed in section 2.1, pre-
existing cardiometabolic complication not only place individ-
ual at risk for worse COVID-19 outcomes, the COVID-19
virus may lead to cardiovascular complications [1]. Moving
forward, it remains unclear as to what the long-term impact
will be in terms of COVID-19-related cardiovascular com-
plications, and what the impact of such complications may
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be on direct healthcare costs, long-term rehabilitation costs,
lost work days, and productivity losses? Additionally, what
are the consequences to universal healthcare? And for coun-
tries such as the United States, which has a highly privatized
healthcare system, what will be the ramifications for health-
care premiums [10]?
2.6 The need for data
The Covid-19 Effects on ARTErial StIffness and Vascular
AgeiNg (CARTESIAN) study is a longitudinal international
multicenter study investigating the long-term consequences
of COVID-19 to vascular health [11]. A secondary objective
of CARTESIAN is to evaluate whether the effects of COVID-
19 on the vascular system are moderate by psychosocial, co-
morbidities, and chronic treatment. Such data will be cru-
cial in terms of identifying which factors influence the long-
term vascular complications of CVOID-19, and for directing
treatment strategies. Though additional data will be needed,
including with respect to prevalence and risk factors among
underserved population, identifying lifestyle strategies for
mitigating the long-term cardiometabolic consequences of
COVID-19, and identifying the best use of public health re-
sources. Data is needed to address these and many additional
foreseeable and unforeseeable questions. Our hope is that re-
search teams will details the types of data they are using, pre-
existing questions being tackledwith their data, and their pol-
icy for sharing data.
2.7 Public health policy
Across the globe, Goliath-esque challenges are being pre-
sented to public health agencies. These agencies will have a
crucial role to play long following the ablation of COVID-
19 restrictions. Considering the widespread consequences of
this [hopefully] once-in-a-lifetime pandemic, what types of
policy should be implemented to ensure these agencies are
best positioned to be proactive with foreseeable challenges
and to react to unforeseen challenges? Which segments of
the population should be primarily targeted? What forms of
education are required to ensure the public is amenable to
booster shots? Who should pay for booster shots?
3. Conclusions
Above we presented some of the many questions that 
need to be addressed to limit the short-and long-term car-
diometabolic consequences of COVID-19. Our intention was 
not to be exhaustive, but rather to illuminate some of the 
many questions we, as a research community, need to address 
to be of service to the public. On behalf of HL-PIVOT and 
EIM we welcome stimulating and open discourse.
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